S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Catalyst Pharmaceuticals Stock Forecast, Price & News

+0.07 (+1.02%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
751,589 shs
Average Volume
1.15 million shs
Market Capitalization
$714.32 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock Forecast (MarketRank)

Overall MarketRank

2.99 out of 5 stars

Medical Sector

18th out of 1,432 stocks

Pharmaceutical Preparations Industry

3rd out of 685 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 3.1 5 -4 -3 -2 -1 -
Catalyst Pharmaceuticals logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock News Headlines

3 Robinhood Favs the Street Loves Too (CPRX)
Given the largely speculative nature of the Robinhood-100 list, it’s not often that fundamentally focused research firms agree with the largely social media-driven retail trader. Yet the Street and Robinhooders are clearly on board with the growth potential of these three names.
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$39.48 million
Pretax Margin


Sales & Book Value

Annual Sales
$140.83 million
Cash Flow
$0.41 per share
Book Value
$2.01 per share


Free Float
Market Cap
$714.32 million

Social Links

Catalyst Pharmaceuticals Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2022?

4 brokers have issued twelve-month target prices for Catalyst Pharmaceuticals' stock. Their CPRX stock forecasts range from $8.75 to $12.00. On average, they predict Catalyst Pharmaceuticals' share price to reach $10.92 in the next year. This suggests a possible upside of 57.1% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Catalyst Pharmaceuticals' stock price performed in 2022?

Catalyst Pharmaceuticals' stock was trading at $6.77 at the beginning of the year. Since then, CPRX shares have increased by 2.7% and is now trading at $6.95.
View the best growth stocks for 2022 here

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Catalyst Pharmaceuticals

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.14 by $0.02. The biopharmaceutical company had revenue of $43.09 million for the quarter, compared to analysts' expectations of $43.17 million. Catalyst Pharmaceuticals had a net margin of 29.31% and a trailing twelve-month return on equity of 23.95%. During the same period in the prior year, the company posted $0.09 EPS.
View Catalyst Pharmaceuticals' earnings history

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $195.00 million-$205.00 million, compared to the consensus revenue estimate of $199.99 million.

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 75, Pay $1.05M) (LinkedIn Profile)
  • Ms. Alicia Grande C.M.A., CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO (Age 51, Pay $617.94k)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 60, Pay $745.71k)
  • Dr. Gary Ingenito, Chief Medical & Regulatory Officer (Age 66, Pay $706.86k) (LinkedIn Profile)
  • Dr. Preethi Sundaram Ph.D., Chief Strategy Officer (Age 46, Pay $511.25k)
  • Ms. Mary Coleman, VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D., Chief Compliance Officer & Chief Legal Officer (Age 58)
  • Mr. Pete Curry Sr., VP of Sales
  • Mr. Jeffrey Del Carmen, Chief Commercial Officer (Age 51)
  • Mr. Philip B. Schwartz, Corp. Sec. (Age 67)

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $6.95.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $714.32 million and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.42 on an earnings per share basis.

How many employees does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals employs 76 workers across the globe.

When was Catalyst Pharmaceuticals founded?

Catalyst Pharmaceuticals was founded in 2002.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for Catalyst Pharmaceuticals is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at [email protected], or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.